Dr. Gerhardt Attard continues his discussion of the STAMPEDE trial by focusing on the identification of patients who may not experience improved survival rates from the study's treatment combination.
The Decipher score demonstrated a notable benefit in predicting patient survival rates, providing a nearly 40% reduction in patient hazard ratios during the trial.
